BRPI0513551A - uso de equivalentes de aspartato e pelo menos um de vitamina b12 e biotina, e, composição nutricional enteral - Google Patents
uso de equivalentes de aspartato e pelo menos um de vitamina b12 e biotina, e, composição nutricional enteralInfo
- Publication number
- BRPI0513551A BRPI0513551A BRPI0513551-6A BRPI0513551A BRPI0513551A BR PI0513551 A BRPI0513551 A BR PI0513551A BR PI0513551 A BRPI0513551 A BR PI0513551A BR PI0513551 A BRPI0513551 A BR PI0513551A
- Authority
- BR
- Brazil
- Prior art keywords
- equivalents
- lactate
- ketone
- vitamin
- biotin
- Prior art date
Links
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 title abstract 7
- 239000000203 mixture Substances 0.000 title abstract 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 title abstract 3
- 229940009098 aspartate Drugs 0.000 title abstract 3
- 235000020958 biotin Nutrition 0.000 title abstract 3
- 239000011616 biotin Substances 0.000 title abstract 3
- 229960002685 biotin Drugs 0.000 title abstract 3
- 235000016709 nutrition Nutrition 0.000 title abstract 3
- RMRCNWBMXRMIRW-WYVZQNDMSA-L vitamin b12 Chemical compound N([C@@H]([C@@]1(C)[C@@](C)(CC(N)=O)[C@H](CCC(N)=O)\C(N1[Co+]C#N)=C(/C)\C1=N\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NCC(C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO RMRCNWBMXRMIRW-WYVZQNDMSA-L 0.000 title 1
- 150000002576 ketones Chemical class 0.000 abstract 5
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 abstract 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 2
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 abstract 2
- 229930195712 glutamate Natural products 0.000 abstract 2
- 235000000638 D-biotin Nutrition 0.000 abstract 1
- 239000011665 D-biotin Substances 0.000 abstract 1
- 229930003779 Vitamin B12 Natural products 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000013632 homeostatic process Effects 0.000 abstract 1
- 230000037447 lactate metabolism Effects 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 235000005985 organic acids Nutrition 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000000472 traumatic effect Effects 0.000 abstract 1
- 239000011715 vitamin B12 Substances 0.000 abstract 1
- 235000019163 vitamin B12 Nutrition 0.000 abstract 1
- 229940045999 vitamin b 12 Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
- A23L13/40—Meat products; Meat meal; Preparation or treatment thereof containing additives
- A23L13/42—Additives other than enzymes or microorganisms in meat products or meat meals
- A23L13/424—Addition of non-meat animal protein material, e.g. blood, egg, dairy products, fish; Proteins from microorganisms, yeasts or fungi
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
- A23L13/60—Comminuted or emulsified meat products, e.g. sausages; Reformed meat from comminuted meat product
- A23L13/65—Sausages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L23/00—Soups; Sauces; Preparation or treatment thereof
- A23L23/10—Soup concentrates, e.g. powders or cakes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
Abstract
USO DE EQUIVALENTES DE ASPARTATO E PELO MENOS UM DE VITAMINA B12 E BIOTINA, E, COMPOSIçãO NUTRICIONAL ENTERAL Foi verificado que quantidades altas de equivalentes de aspartato em combinação com vitamina B12 e/ou biotina, especialmente na ausência relativa de equivalentes de glutamato, melhoram o metabolismo de corpos de cetona e/ou lactato em um corpo de mamífero, especialmente em condições de doença ou traumáticas. Como um resultado, níveis de níveis de corpos de cetona e lactato podem ser diminuídos e a acidez não fisiologicamente alta normalizada. Assim, é um objetivo da invenção fornecer uma composição nutricional enteral ou farmacêutica para o tratamento e/ou prevenção do metabolismo de cetona e lactato perturbado, isto e, concentrações elevadas de corpos de cetona, lactato e/ou outros ácidos orgânicos e/ou homeostase em pH insuficiente, especialmente concentrações elevadas de corpos de cetona e/ou lactato, em um sangue de mamífero, em que a composição compreende quantidades altas de equivalentes de aspartato em combinação com vitamina B 12 e/ou biotina, preferivelmente na ausência relativa de equivalentes de glutamato.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58879304P | 2004-07-19 | 2004-07-19 | |
EP04077100 | 2004-07-19 | ||
EP04077359 | 2004-08-20 | ||
PCT/NL2005/000520 WO2006009438A2 (en) | 2004-07-19 | 2005-07-18 | Preparation for use of aspartate and vitamin b12 or biotin for regulating ketone bodies |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0513551A true BRPI0513551A (pt) | 2008-05-06 |
Family
ID=35714682
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0513551-6A BRPI0513551A (pt) | 2004-07-19 | 2005-07-18 | uso de equivalentes de aspartato e pelo menos um de vitamina b12 e biotina, e, composição nutricional enteral |
BRPI0513500 BRPI0513500C8 (pt) | 2004-07-19 | 2005-07-18 | Uso de equivalentes de aspartato e composição nutricional ou farmacêutica |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0513500 BRPI0513500C8 (pt) | 2004-07-19 | 2005-07-18 | Uso de equivalentes de aspartato e composição nutricional ou farmacêutica |
Country Status (13)
Country | Link |
---|---|
US (5) | US8003600B2 (pt) |
EP (3) | EP1771191B1 (pt) |
JP (2) | JP2008506771A (pt) |
CN (3) | CN103734746B (pt) |
BR (2) | BRPI0513551A (pt) |
CA (2) | CA2574423A1 (pt) |
DK (2) | DK2705849T3 (pt) |
ES (3) | ES2673195T3 (pt) |
NZ (1) | NZ552706A (pt) |
PL (3) | PL1771192T3 (pt) |
RU (1) | RU2633071C2 (pt) |
TR (1) | TR201809368T4 (pt) |
WO (2) | WO2006009437A2 (pt) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008506771A (ja) * | 2004-07-19 | 2008-03-06 | エヌ.ブイ.・ヌートリシア | 血糖値を調節するためのアスパルテートを使用するための調製物 |
KR101233648B1 (ko) * | 2004-09-29 | 2013-02-15 | 시즈오카켄 | 유청 단백, 젖 유래의 항체 또는 항체를 포함하는 기능성조성물 또는 식품 |
CA2642429A1 (en) * | 2005-02-17 | 2006-08-24 | Instituto Del Metabolismo Celular, S.L. | L-aspartic acid for the treatment of problems in connection with the fat or glucose metabolism |
EP1774973A1 (en) * | 2005-10-12 | 2007-04-18 | Nutricia N.V. | Leucine rich composition |
WO2008054192A1 (en) * | 2006-11-02 | 2008-05-08 | N.V. Nutricia | Use of nutritional compositions for preventing disorders |
EP1800675B1 (en) * | 2005-12-23 | 2011-05-18 | N.V. Nutricia | Composition comprising polyunsaturated fatty acids, proteins, manganese and/or molybden and nucleosides/nucleotides for treating dementia |
ES2537080T3 (es) * | 2005-12-23 | 2015-06-02 | N.V. Nutricia | Composición que comprende ácidos grasos poliinsaturados, proteínas y manganeso y/o molibdeno para mejorar la composición de membranas celulares |
AU2006340316B2 (en) * | 2006-03-23 | 2013-03-28 | Nestec S.A. | High-calorie nutritional supplement |
JP2010505420A (ja) * | 2006-10-06 | 2010-02-25 | ネステク ソシエテ アノニム | 生理的健康の生物学的媒介物質を測定するための組成物及び多重アッセイ |
WO2008054193A1 (en) | 2006-11-02 | 2008-05-08 | N.V. Nutricia | Nutritional products that comprise saccharide oligomers |
DK2044853T3 (da) | 2007-10-02 | 2011-06-14 | Isme Privates Forschungsinstitut Fuer Sport Medizin Und Ernaehrung Gmbh | Næringsstof til anvendelse til accelereret fysiologisk præstationsforbedring |
US8651126B2 (en) | 2007-11-21 | 2014-02-18 | Teva Pharmaceutical Industries, Ltd. | Controllable and cleanable steam trap apparatus |
WO2010002242A1 (en) | 2008-07-02 | 2010-01-07 | N.V. Nutricia | Nutritional composition for improving muscle function and daily activity |
CA2676518A1 (en) * | 2008-08-29 | 2010-02-28 | Kraft Foods Global Brands Llc | Whey protein pre-load |
US20110229447A1 (en) * | 2008-09-19 | 2011-09-22 | Eduardo Schiffrin | Nutritional support to prevent or moderate bone marrow paralysis or neutropenia during anti-cancer treatment |
WO2010104374A1 (en) * | 2009-03-09 | 2010-09-16 | N.V. Nutricia | Nutritional composition inducing a postprandial endocrine response |
WO2010112060A1 (en) * | 2009-03-30 | 2010-10-07 | Isme Privates Forschungsinstitut Für Sport, Medizin Und Ernährung Gmbh | Nutriment for use for accelerated physiological perfomance enhancement |
MY161505A (en) | 2009-04-01 | 2017-04-14 | Nestec Sa | Reduction of risk of obesity |
US8703719B1 (en) * | 2009-05-18 | 2014-04-22 | Bio-Engineered Supplements And Nutrition, Inc. | Method and composition for improved muscle performance |
WO2011021926A1 (en) * | 2009-08-21 | 2011-02-24 | N.V. Nutricia | Regulating the amino acid pool used for the acute-phase protein synthesis |
WO2012074375A1 (en) | 2010-12-01 | 2012-06-07 | N.V. Nutricia | Prevention or treatment of overweight and obesity in type 2 diabetic patients |
US20140030241A1 (en) * | 2011-03-31 | 2014-01-30 | Nestec S.A. | Nutritional compositions for increasing arginine levels and methods of using same |
US20140107193A1 (en) * | 2011-10-14 | 2014-04-17 | Mead Johnson Nutrition Company | Nutritional composition containing a neurologic component of kaempferol and/or fisetin and uses thereof |
IN2015DN03322A (pt) * | 2012-09-21 | 2015-10-09 | Abbott Lab | |
US10668037B2 (en) * | 2012-12-06 | 2020-06-02 | Bio Health Solutions, Llc | Treatment for chronic kidney disease |
US9669010B2 (en) * | 2012-12-06 | 2017-06-06 | Bio Health Solutions, Llc | Treatment for chronic kidney disease |
MY185493A (en) * | 2013-02-15 | 2021-05-19 | Nestle Sa | Food composition and its use |
DK3578185T3 (da) | 2013-06-05 | 2020-11-02 | Tricida Inc | Protonbindende polymerer til oral indgivelse |
US9226914B2 (en) * | 2013-07-16 | 2016-01-05 | Mead Johnson Nutrition Company | Methods for promoting neuronal development and/or health |
US9241923B2 (en) * | 2013-07-16 | 2016-01-26 | Mead Johnson Nutrition Company | Methods for promoting neuronal development and/or health |
US20150119322A1 (en) * | 2013-07-31 | 2015-04-30 | Mead Johnson Nutrition Company | Nutritional compositions containing a prebiotic and lactoferrin and uses thereof |
US9609888B2 (en) * | 2013-07-31 | 2017-04-04 | Mead Johnson Nutrition Company | Nutritional compositions containing synergistic combination and uses thereof |
US10709770B2 (en) * | 2013-07-31 | 2020-07-14 | Mead Johnson Nutrition Company | Nutritional compositions containing a prebiotic and lactoferrin and uses thereof |
US20150164833A1 (en) * | 2013-12-17 | 2015-06-18 | Mead Johnson Nutrition Company | Nutritional composition containing a neurologic component of ursolic acid and uses thereof |
LT3593808T (lt) | 2014-12-10 | 2021-02-25 | Tricida Inc. | Protonus surišantys polimerai, skirti vartojimui per burną |
WO2016205754A1 (en) | 2015-06-19 | 2016-12-22 | University Of Southern California | Compositions and methods for modified nutrient delivery |
WO2016205701A1 (en) | 2015-06-19 | 2016-12-22 | University Of Southern California | Enteral fast access tract platform system |
IL262660B2 (en) | 2016-05-06 | 2024-04-01 | Tricida Inc | Preparations for and method of treating acid-base disorders |
JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
RU2644355C1 (ru) * | 2017-04-17 | 2018-02-09 | федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) | Соединения на основе пиридоксина, обладающие способностью активировать фермент глюкокиназу |
TWI775921B (zh) | 2017-08-14 | 2022-09-01 | 美商胺細拉健康公司 | 用於治療和高血氨症或肌肉耗損中之一者或兩者相關之肝疾病及失調之組合物及方法 |
AU2018360867A1 (en) | 2017-11-03 | 2020-04-30 | Tricida, Inc. | Compositions for and method of treating acid-base disorders |
US10656166B2 (en) | 2017-11-03 | 2020-05-19 | Lysulin, Inc. | Inhibiting chronic blood and nephrological disorders using lysine-based supplements |
US10610544B2 (en) | 2017-11-03 | 2020-04-07 | Lysulin, Inc. | Insulin resistance and beta cell function using lysine-based supplements |
US11255838B2 (en) | 2017-11-03 | 2022-02-22 | Lysulin, Inc. | Levels, functions, and resistances related to chronic conditions by using lysine-based supplements |
US10653720B2 (en) * | 2017-11-03 | 2020-05-19 | Lysulin, Inc. | Prevention of protein glycation using lysine/zinc supplements |
US11197917B2 (en) | 2017-12-01 | 2021-12-14 | ByHeart, Inc. | Formulations for nutritional support in subjects in need thereof |
JP2021527670A (ja) | 2018-06-20 | 2021-10-14 | アクセラ・ヘルス・インコーポレイテッドAxcella Health Inc. | 筋肉中の脂肪浸潤の治療のための組成物及び方法 |
CN110655567B (zh) * | 2019-11-12 | 2021-07-09 | 云南大学 | 食品蛋白的磷酸化方法及其磷酸化蛋白 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1560000A (en) | 1924-08-15 | 1925-11-03 | Beatrice Sanville | Garment button |
US4138498A (en) | 1976-12-07 | 1979-02-06 | W. R. Grace & Co. | Ruminant feed additive |
US5116819A (en) | 1989-05-05 | 1992-05-26 | Clintec Nutrition Co. | Enteral diet for patients with pulmonary disease |
FR2657013B1 (fr) | 1990-01-18 | 1992-05-15 | Medgenix Group Sa | Composition dietetique a base de polypeptides et acides amines. |
US5292773A (en) | 1990-02-14 | 1994-03-08 | Hirsch Gerald P | Treating aids and HIV infection with methionine |
US5356873A (en) * | 1992-11-05 | 1994-10-18 | Clintec Nutrition Co. | Method for providing nutritional requirements to patients having a chronic inflammation reaction |
AU679020B2 (en) * | 1992-12-23 | 1997-06-19 | Abbott Laboratories | Medical foods for the nutritional support of infant/toddler metabolic diseases |
US5470839A (en) | 1993-04-22 | 1995-11-28 | Clintec Nutrition Company | Enteral diet and method for providing nutrition to a diabetic |
GB9312369D0 (en) | 1993-06-16 | 1993-07-28 | Sandoz Nutrition Ltd | Organic compounds |
US5438042B1 (en) * | 1993-10-08 | 1997-08-26 | Sandoz Nutrition Ltd | Enteral nutritional composition having amino acid profile |
AU682894B2 (en) | 1993-10-28 | 1997-10-23 | Institut National De La Recherche Agronomique | Composition based on amino acids intended for the treatment of sepsis or of an attack bringing about an inflammatory reaction, in animals and man |
US5576287A (en) * | 1994-04-29 | 1996-11-19 | Wake Forest University | Method for treating acute renal disease and failure |
GB9409646D0 (en) | 1994-05-13 | 1994-07-06 | Scient Hospital Suppl Int Ltd | Nutritional formulation |
US5550166A (en) * | 1995-03-17 | 1996-08-27 | Ostlund; Richard E. | Pinitol and derivatives thereof for the treatment of metabolic disorders |
JPH0965836A (ja) * | 1995-08-31 | 1997-03-11 | Hokuren Federation Of Agricult Coop:The | α−グルコシダーゼ阻害剤、それを含む糖組成物、甘味料、食品及び飼料 |
MY115050A (en) | 1995-10-16 | 2003-03-31 | Mead Johnson Nutrition Co | Diabetic nutritional product having controlled absorption of carbohydrate |
PL329883A1 (en) | 1996-05-13 | 1999-04-12 | Gist Brocades Bv | Novel food composition |
DE19632452C1 (de) * | 1996-08-12 | 1998-02-19 | Cpc International Inc | Würzsauce, Verfahren zu deren Herstellung und deren Verwendung |
JP2000516937A (ja) * | 1996-08-26 | 2000-12-19 | ヴィス,オスヴァルト | 運動時の酸素消費を低下するビタミン製剤 |
DE19701382A1 (de) | 1997-01-16 | 1998-07-23 | Nutricia Nv | Kohlenhydratmischung |
US6042834A (en) * | 1997-01-29 | 2000-03-28 | Baraka; Mohamed Wasif | Herbal composition for diabetes and method of treatment |
US5922766A (en) | 1997-07-02 | 1999-07-13 | Acosta; Phyllis J. B. | Palatable elemental medical food |
RU2145869C1 (ru) * | 1999-04-30 | 2000-02-27 | Орещенко Андрей Владимирович | Способ антимутагенного воздействия на организм |
CA2274414A1 (en) | 1999-06-11 | 2000-12-11 | Universite Laval | Dietary fish protein for use in restoring normal insulin function insulin-resistant individuals |
US6312755B1 (en) * | 1999-07-16 | 2001-11-06 | Ampc | Whey treatment process for achieving high concentration of α-lactalbumin |
GB9927603D0 (en) * | 1999-11-22 | 2000-01-19 | Nestle Sa | Use of a milk protein hydrolysate in the treatment of diabetes |
GB9929497D0 (en) * | 1999-12-14 | 2000-02-09 | Vitaflo Limited | Improved amino acid mixtures for the treatment and/or management of certain diseases |
ZA200109677B (en) * | 2000-09-06 | 2002-06-25 | Technikon Pretoria | A nutritional and pharmaceutical composition. |
US20040043013A1 (en) | 2000-12-28 | 2004-03-04 | Mccleary Edward Larry | Metabolic uncoupling therapy |
US6743770B2 (en) | 2001-02-14 | 2004-06-01 | Functional Foods, Inc. | Nutritional supplement for the management of stress |
CN1193691C (zh) * | 2001-02-28 | 2005-03-23 | 陈胜利 | 中老年人养生保健饮料及制备方法 |
US6720312B2 (en) | 2001-03-16 | 2004-04-13 | Heartland Health Solutions, Llc | Method for controlling the membrane structure of a starch granule |
US20030000391A1 (en) | 2001-06-12 | 2003-01-02 | Jay Highman | Organic nutritional formula |
US20040234631A1 (en) | 2001-07-03 | 2004-11-25 | Hoie Lars Henrik | Composition comprising soy and use thereof in the provention and/or treatment of various diseases |
US6503530B1 (en) | 2001-11-01 | 2003-01-07 | Chunghee Kimberly Kang | Method of preventing development of severe metabolic derangement in inborn errors of metabolism |
US20030118663A1 (en) * | 2001-12-24 | 2003-06-26 | Ching-Ming Chang | Method and composition for treating diabetes |
US6916796B2 (en) | 2002-06-12 | 2005-07-12 | Abbott Laboratories | Use of pullulan as a slowly digested carbohydrate |
GB0213612D0 (en) | 2002-06-13 | 2002-07-24 | Novartis Nutrition Ag | Organic compounds |
GB0221184D0 (en) | 2002-09-13 | 2002-10-23 | Cerestar Holding Bv | Carbohydrate materials in food and drink compositions |
US6706697B1 (en) * | 2002-09-19 | 2004-03-16 | Jason Pharmaceuticals, Inc. | Diabetic nutrition and weight loss drink compositions |
CA2507764A1 (en) * | 2002-12-20 | 2004-07-08 | Unilever Plc | Blood glucose regulating composition |
JP2008506771A (ja) * | 2004-07-19 | 2008-03-06 | エヌ.ブイ.・ヌートリシア | 血糖値を調節するためのアスパルテートを使用するための調製物 |
-
2005
- 2005-07-18 JP JP2007522447A patent/JP2008506771A/ja active Pending
- 2005-07-18 PL PL05762926T patent/PL1771192T3/pl unknown
- 2005-07-18 TR TR2018/09368T patent/TR201809368T4/tr unknown
- 2005-07-18 EP EP05762925.5A patent/EP1771191B1/en not_active Revoked
- 2005-07-18 US US11/572,197 patent/US8003600B2/en not_active Expired - Fee Related
- 2005-07-18 PL PL05762925T patent/PL1771191T3/pl unknown
- 2005-07-18 NZ NZ552706A patent/NZ552706A/en not_active IP Right Cessation
- 2005-07-18 CA CA002574423A patent/CA2574423A1/en not_active Abandoned
- 2005-07-18 WO PCT/NL2005/000519 patent/WO2006009437A2/en active Application Filing
- 2005-07-18 WO PCT/NL2005/000520 patent/WO2006009438A2/en active Application Filing
- 2005-07-18 EP EP13152810.1A patent/EP2705849B1/en not_active Revoked
- 2005-07-18 PL PL13152810T patent/PL2705849T3/pl unknown
- 2005-07-18 ES ES13152810.1T patent/ES2673195T3/es active Active
- 2005-07-18 DK DK13152810.1T patent/DK2705849T3/en active
- 2005-07-18 BR BRPI0513551-6A patent/BRPI0513551A/pt not_active Application Discontinuation
- 2005-07-18 US US11/632,871 patent/US8501676B2/en not_active Expired - Fee Related
- 2005-07-18 RU RU2010140355A patent/RU2633071C2/ru active
- 2005-07-18 ES ES05762926T patent/ES2700463T3/es active Active
- 2005-07-18 ES ES05762925.5T patent/ES2467093T3/es active Active
- 2005-07-18 DK DK05762925.5T patent/DK1771191T3/da active
- 2005-07-18 CN CN201310722533.6A patent/CN103734746B/zh active Active
- 2005-07-18 BR BRPI0513500 patent/BRPI0513500C8/pt active IP Right Grant
- 2005-07-18 JP JP2007522448A patent/JP2008506772A/ja active Pending
- 2005-07-18 EP EP05762926.3A patent/EP1771192B1/en not_active Revoked
- 2005-07-18 CA CA002574360A patent/CA2574360A1/en not_active Abandoned
- 2005-07-18 CN CN200580031377.2A patent/CN101022821B/zh active Active
- 2005-07-18 CN CNA2005800304665A patent/CN101018561A/zh active Pending
-
2011
- 2011-08-01 US US13/195,831 patent/US8865649B2/en not_active Expired - Fee Related
-
2013
- 2013-07-15 US US13/941,625 patent/US9889149B2/en not_active Expired - Fee Related
-
2014
- 2014-10-16 US US14/516,129 patent/US9539278B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0513551A (pt) | uso de equivalentes de aspartato e pelo menos um de vitamina b12 e biotina, e, composição nutricional enteral | |
BRPI0415480A (pt) | composição nutricional contra efeitos colaterais de quimioterapia ou radioterapia | |
RU2014122168A (ru) | Улучшение памяти у пациентов с оценкой 24-26 баллов по краткой шкале оценки психического статуса | |
CY1115416T1 (el) | Συνθεση που περιεχει στατινες και ωμεγα-3 λιπαρα οξεα | |
BRPI0706676B8 (pt) | uso de uma solução aquosa com potencial de oxirredução | |
BRPI0810179B8 (pt) | composições de oligoguluronato e galacturonato e usos dos mesmos | |
BR112018015097A2 (pt) | composição e reatores | |
BRPI0610786B8 (pt) | uso de um ou mais oligossacarídeos ácidos e neutros, e cisteína e/ou fonte de cisteína, e, composição alimentícia | |
AR052837A1 (es) | Composiciones que contienen hierro | |
BR112014032905A2 (pt) | métodos de redução do risco de um evento cardiovascular em um sujeito em terapia com estatina | |
ATE534393T1 (de) | Zusammenstellungen zur energiesteigerung in vivo | |
BRPI0518565A2 (pt) | composiÇÕes cardiovasculares | |
AR022076A1 (es) | Composicion antioxidante constituida por acetil l-carnitina y acido alfa-lipoico para mejorar el aprovechamiento metabolico de la glucosa | |
BRPI0905369B8 (pt) | composição farmacêutica, uso da composição farmacêutica e kit compartimentado | |
AR044007A1 (es) | Metodos para el tratamiento de la enfermedad de parkinson | |
GT200600463A (es) | Derivados de carbamoilbenzotriazol como inhibidores de lipasas y fosfolipasas | |
BR112019023981A2 (pt) | injeção de octreotida | |
BRPI0513938B8 (pt) | composição farmacêutica contendo drospirenona e etinilestradiol | |
BR112022018645A2 (pt) | Composições e métodos para tratar ou prevenir doenças inflamatórias, incluindo diabetes mellitus tipo i e tipo ii e doenças da tireoide | |
BR112016000658A2 (pt) | pancreatina de alta atividade, processo para a preparação de pancreatina de aa tendo atividade lipásica específica de pelo menos aproximadamente 120 usp iu/mg e método de tratamento de um paciente sujeito a uma condição patológica associada com a insuficiência enzimática pandreática | |
BRPI0517132A (pt) | regime de cladribina para o tratamento da esclerose múltipla | |
BRPI0921917B8 (pt) | formulação farmacêutica. | |
AR051932A1 (es) | Ciertas plantas con niveles de acidos grasos "no saturados", o saturados reducidos en semillas, y aceite derivado de las semillas | |
ES2629309T3 (es) | Formulaciones de tratamiento de la mucositis inducida por terapia antitumoral o inmunosupresora | |
Liu et al. | Suppression effects of betaine-enriched spinach on hyperhomocysteinemia induced by guanidinoacetic acid and choline deficiency in rats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] |